The less Mylan and the Justice Department say about their big settlement over EpiPen, the more Congress wants to hear about it.
The Senate Judiciary Committee will hold a hearing Nov. 30 to examine Mylan’s agreement to pay the federal government $465 million to settle potential claims that the big drug company shortchanged Medicaid over rebates for sales of the anti-allergy EpiPen devices.
The hearing was called by committee chairman Sen. Chuck Grassley, R-Iowa. He is just one of several senators who has expressed frustration over the deal, with some calling for more disclosure about yet-to-be-signed agreement or for it to be scrapped altogether.
